TLR7 and neoplasm: The addition of Resiquimod (R848), a TLR7/8 agonist, prevented tumor recurrence in 60% of mice while adjuvant DMXAA did not enhance long-term survival compared to CA alone, both resulting in an overall survival of 40% (Figure 1A).